HCmed Innovations Co., Ltd. (TPE:6934)

Market Cap	2.81B +34.0%
Revenue (ttm)	100.23M -29.2%
Net Income	-126.11M
EPS	-3.92
Shares Out	32.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,860
Average Volume	266,119
Open	87.10
Previous Close	85.30
Day's Range	82.40 - 87.90
52-Week Range	45.45 - 175.00
Beta	n/a
RSI	48.74
Earnings Date	May 15, 2026

About HCmed Innovations

HCmed Innovations Co., Ltd. designs, develops, manufactures, and sells respiratory drug delivery systems in the United States, Europe, Africa, and Asia. The company’s products include Pulmogine, a vibrating mesh nebulizer to nebulize a range of liquid medications to treat respiratory diseases and their symptoms in children and adults; and AdheResp, a breath-actuated mesh nebulizer for consumers and healthcare professionals. It also provides intellectual property, advanced technology, customization platforms, manufacturing and commercialization,...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6934

Financial Performance

In 2025, HCmed Innovations's revenue was 100.23 million, a decrease of -29.22% compared to the previous year's 141.61 million. Losses were -126.11 million, 61.2% more than in 2024.